

Strategies to Alter the Natural History of Childhood Asthma

K.A. Lee-Sarwar; L.B. Bacharier; A.A. Litonjua |

Curr Opin Allergy Clin Immunol. 2017;17(2):139-145.



Abstract and Introduction

Abstract

Purpose of review Asthma exhibits significant heterogeneity in occurrence and severity over the lifespan. Our goal is to discuss recent evidence regarding determinants of the natural history of asthma during childhood, and review the rationale behind and status of major efforts to alter its course.

Recent findings Variations in microbial exposures are associated with risk of allergic disease, and the use of bacterial lysates may be a promising preventive strategy. Exposure to air pollution appears to be particularly damaging in prenatal and early life, and interventions to reduce pollution are feasible and result in clinical benefit. E-cigarette use may have a role in harm reduction for conventional cigarette smokers with asthma, but has undefined short-term and long-term effects that must be clarified. Vitamin D insufficiency over the first several years of life is associated with risk of asthma, and vitamin D supplementation reduces the risk of severe exacerbations.

Summary The identification of risk factors for asthma occurrence, persistence and severity will continue to guide efforts to alter the natural history of the disease. We have reviewed several promising strategies that are currently under investigation. Vitamin D supplementation and air pollution reduction have been shown to be effective strategies and warrant increased investigation and implementation.

Introduction

Asthma is a developmental disease: the majority of cases are diagnosed by age 6,^[1] and lung function abnormalities may be present in early infancy.^[2–4] However, diagnosis in early childhood may be difficult as preschool wheeze has a variety of causes including bronchiolitis.^[5,6] Almost 50% of children report wheeze before age 6, but 40% of these children experience resolution of wheeze between the ages of 3 and 6.^[7]

The existence of distinct trajectories of childhood wheeze, and of asthma more generally, represents a challenge to the elucidation of the natural history of the disease. Several phenotypes of preschool wheeze have been identified and indices have been developed to predict the development of subsequent asthma by midchildhood.^[8,9] Children with preschool wheeze in the Tucson Children's Respiratory Study cohort were categorized in three groups: early transient wheezers with symptoms by age 3 and resolution by age 6, persistent wheezers with symptoms by age 3 that persisted at age 6 and late-onset wheezers with symptom onset between ages 3 and 6.^[7] Approaches employing machine learning computational techniques to distinguish asthma phenotypes have largely corroborated the existence of groups defined by early life wheeze (transient or prolonged), late-onset wheeze and persistent wheeze (controlled or troublesome).^[10,11] This work has led to the identification of major risk factors for persistent wheeze, including atopy, relatively high asthma morbidity in early life and maternal history of asthma.^[5,6,10]

Although childhood wheeze may resolve by adulthood,^[12,13] lung function abnormalities frequently persist later in life.^[14–16] A recent study^[17] demonstrated distinct trajectories of lung function in nearly 700 children with mild-to-moderate asthma followed to an average age of 26 with annual lung function assessments. Four patterns were identified based on forced expiratory volume in 1 second (FEV1)

measurements with approximately equal numbers of individuals in each group: normal lung development, normal lung growth with an early decline in lung function, reduced lung growth with no early decline in lung function and reduced lung growth with an early decline in lung function. Risk factors for abnormal longitudinal patterns include maternal smoking, reduced lung function at enrollment, increased airway hyperresponsiveness, vitamin D insufficiency and male sex.

Although additional research is needed to further characterize asthma subtypes and determinants of their courses over the lifespan, there have been advances in strategies to alter the natural history of asthma. In this review, we discuss medical management in early childhood, prevention of smoke and air pollution exposure, modification of microbial exposures and vitamin D supplementation. Other relevant topics reviewed elsewhere in this issue include allergy and viral respiratory infection prevention (reviewed by Daniel Jackson) and prenatal exposures (reviewed by Tina Hartert).

Medical Management in Early Childhood

Among medical treatments for control of recurrent preschool wheeze, which are reviewed in this issue by Avraham Beigelman, inhaled corticosteroid use has accrued the most evidence of effectiveness, [18–21] with less evidence supporting the use of leukotriene inhibitors.^[22] A recent multicenter randomized crossover trial demonstrated heterogeneity in response to treatment: 74% of 230 children aged 12–59 months who require a daily controller medication had a differential response to treatment with daily inhaled corticosteroids, intermittent inhaled corticosteroids and leukotriene receptor antagonists. Of those with differential response to treatment, daily inhaled corticosteroids had the highest probability of producing the best response.^[23]

As the prevalence of and morbidity from asthma and wheeze are high during early childhood, interventions during this period may be expected to impact lung function and asthma control later in life. Unfortunately, randomized placebo-controlled trials have not found that inhaled corticosteroid treatment during the preschool years alters the natural history of asthma or persistent wheeze,^[24–26] though no trials have investigated the consistent and long-term use of daily controller therapy.^[5] Anti-immunoglobulin E therapy with omalizumab is currently under investigation as a treatment to prevent asthma in high-risk preschool children (NCT02570984).

Prevention of Smoke Exposure in the Electronic-cigarette Era

There is abundant evidence that smoke exposure worsens^[27–31] and smoking cessation improves^[32,33] asthma control and lung function. Electronic cigarettes, or e-cigarettes, are battery-powered nicotine delivery systems that are thought to reduce toxic and carcinogenic exposures compared with combustible conventional cigarettes.^[34–36]

E-cigarette use has become widespread in the United States. In 2014, 12.6% of adults had ever used an e-cigarette, and 3.7% were current users.^[37] The majority of adult users of e-cigarettes were current or former users of conventional cigarettes, suggesting that e-cigarettes do not promote widespread initiation of smoking or relapse in those with remote smoking histories.^[37] However, e-cigarette use is also frequent in adolescents, with 44.9% of students in grades 9–12 reporting having ever used an electronic vapor product,^[38] and 5.3% of middle school and 16.0% of high school students reporting current e-cigarette use in 2015.^[39] In Florida, e-cigarette use among high school students in 2012 was actually more frequent among students who reported having asthma than among those without asthma.^[40] Although these numbers may decrease with the ban on sale of e-cigarettes to those under age 18 implemented in 2016 in the United States, they raise concern that e-cigarettes may promote initiation of smoking among adolescents and young adults, including those with asthma.

On the contrary, though evidence is mixed regarding the effectiveness of e-cigarette use for smoking cessation,^[36,41,42] it may be useful for harm reduction in smokers with asthma. A prospective study of

18 individuals with mild-to-moderate asthma who switched from conventional to e-cigarette use found significant improvements over 2 years of follow-up in respiratory symptoms, lung function, airway hyperresponsiveness and tobacco consumption with no significant change in asthma exacerbation rate.^[43,44] Despite this encouraging research, toxicity varies significantly between e-cigarette products^[45,46] and long-term effects of e-cigarette use remain unknown.^[34–36] Until these effects are clarified, other safer methods of smoking cessation should be used before e-cigarettes in patients with asthma.

Prevention of Early Life Exposure to Air Pollution

Exposure to air pollutants, such as nitrogen dioxide, ozone and particulate matter, is a major risk factor for abnormal lung development and function^[47–51] and has been linked to increased asthma prevalence and reduced asthma control.^[52–60] Recent evidence highlights the impact of air pollution exposure in prenatal and early life on lung function later in life. Schultz *et al.*^[61] reported on longitudinal exposure to nitric oxide and particulate matter with an aerodynamic diameter of less than 10 μm in 2278 individuals followed from birth.^[62] There was a negative association between air pollution exposure in the first year of life and FEV1 at age 16, and later air pollution exposures appeared to have additional negative effects. Another study^[63] utilizing administrative databases of medical visits over a 10-year period in a Canadian population-based cohort of over 65 000 individuals found that prenatal nitrogen dioxide exposure was associated with asthma that persisted past age 6, but not with 'transient asthma' that resolved by age 6.

Interventions to reduce air pollution are feasible and result in demonstrable benefit. Between 1994 and 2011, aggressive pollution reduction strategies were implemented in southern California. Over this period, three separate large cohorts of children were followed between the ages of 11 and 15 including annual lung function measurements.^[64] Improvements in 4-year growth of FEV1 and forced vital capacity were associated with declining levels of nitrogen dioxide and particulate matter with aerodynamic diameters less than 2.5 μm and less than 10 μm . This association held in children both with and without asthma, and the proportion of children with FEV1 values of less than 80% of the predicted value at age 15 declined significantly from 7.9% to 6.3% to 3.6% across the three cohorts. This important study builds on prior research showing reduced asthma morbidity in association with decreased traffic during the Olympic Games in both Atlanta in 1996 and Beijing in 2008.^[65–67]

Potential Benefit of Immunostimulant Microbial Exposures

The ecological community inside and outside the body has emerged as a major environmental exposure of interest in asthma pathogenesis. Culture-independent high-throughput methods have revolutionized the identification and quantification of genetic material, and knowledge has rapidly accumulated regarding the microbial composition of human living environments and bodies.^[68,69] These developments occurred concomitantly with the proposal and evolution of the 'hygiene hypothesis,' which posits that reduced microbial exposure accounts for the rising prevalence of allergic disease.^[70]

The hygiene hypothesis is based on the now well documented finding that risk of allergic disease is reduced in association with a variety of environmental exposures, among which household size was the first to be identified.^[68–70] Wu *et al.*^[71] recently showed that exposures in early infancy may be particularly important. In a population-based birth cohort of 136 098 infants, maternal urinary tract infection and antibiotic use during pregnancy, mode of delivery, infant antibiotic use and having older siblings at home were associated in a cumulative and dose-dependent manner with increased risk of childhood asthma; of these, infant antibiotic use was the strongest predictor.

As many of the same exposures that are linked to reduced risk of allergy have come to be recognized as determinants of human microbial composition, including residence on a farm, cohabitation with a dog, day care attendance and vaginal birth, the hygiene hypothesis has evolved into a 'microbiota

hypothesis' in which environmental factors reduce allergic disease via modification of the host microbiome.^[68,69,72] Other recognized asthma risk factors may also act via perturbations of the human microbiome. For example, acute respiratory syncytial virus infection during infancy is associated with a nasopharyngeal microbiome composition similar to the composition seen in infants who later develop asthma.^[73]

The microbiota hypothesis is supported by a growing body of evidence. The gut microbiome differs between those with and without asthma,^[74–76] and between members of communities with different degrees of industrialization and prevalence of allergic disease.^[68,72,77] Oropharyngeal colonization and gut microbiome composition as early as age 1 month have been associated with risk of subsequent atopy and asthma.^[78–81] Evidence primarily from animal models demonstrates a role of the gut microbiome in the development of immune tolerance mechanisms,^[82] and exposure to bacterial species associated with protection from allergic disease in human studies^[74,83–85] has been shown to reduce experimentally induced airway inflammation in mice.

Synthesizing and building on this body of evidence, Stein *et al.*^[86] recently reported on children from Hutterite and Amish agricultural communities in the United States. These populations have similar ancestry and agricultural lifestyles, but Hutterites use more industrialized farming practices. Hutterite children demonstrated higher prevalence of allergic disease, differences in the microbial composition of dust in participants' homes and differences in innate immune cell frequencies and phenotypes compared with Amish children. In a mouse model, intranasal dust extracts from Amish, but not Hutterite, homes significantly inhibited airway hyperreactivity and eosinophilia.

It may soon be possible to predict risk of asthma based on early infancy microbiome data. Fujimura *et al.*^[87] recently used 16S rRNA sequencing of stool samples provided between ages 1 and 11 months to categorize 298 birth cohort participants into three distinct microbiota compositional states, each of which was associated with significantly different risk for multisensitized atopy at age 2 and doctor-diagnosed asthma at age 4.

The recognition of a connection between early microbial interactions and risk of asthma has led to attempts to modify gut colonization to prevent asthma. Unfortunately, several randomized trials have failed to show that prenatal and early life probiotic and prebiotic treatments reduce asthma incidence.^[88–94]

Bacterial lysates, immunoregulatory cellular extracts that have been found to reduce allergic airway inflammation in mouse models, may be an effective alternative.^[95–97] The most studied bacterial lysate is OM-85 BV, which contains extracts derived from eight bacterial species: *Staphylococcus aureus*, *Streptococcus* species, *Klebsiella* species, *Neisseria catarrhalis* and *Haemophilus influenzae*. Several trials, though generally small and with significant heterogeneity, have demonstrated that bacterial lysate treatment reduces recurrent respiratory tract infections in adults and children,^[98–101] and OM-85 BV has been used for decades for this indication in Europe.^[95] A small clinical trial of 75 children between ages 1 and 6 with recurrent wheeze found a nearly 40% reduction in number of wheezing attacks and a reduction in duration of wheezing attacks over 1 year of follow-up in those randomized to OM-85 BV treatment.^[102] Nonrandomized clinical data further support a potential benefit of OM-85 BV in asthma.^[103] The effectiveness of OM-85 BV in preventing severe wheezing lower respiratory tract infection in high-risk infants is currently under study in a multicenter placebo-controlled randomized clinical trial (NCT02148796).

Vitamin D Supplementation

Vitamin D deficiency is common worldwide and several of its myriad physiological consequences are central to asthma pathogenesis, including effects on lung development and immune function.^[104–108] The role of vitamin D over the first decade of life was recently studied by Hollams *et al.*^[109] in a birth cohort of children at high risk of asthma that measured 25-hydroxyvitamin D levels at seven visits between birth and age 10. Although there was no overall longitudinal association between vitamin D

level and asthma or wheeze, in a subgroup of 80 individuals in whom vitamin D levels were available from all follow-up visits, the total number of vitamin D-deficient follow-ups per child was positively associated with asthma and wheeze at age 10. There were inverse relationships between vitamin D levels and early allergic sensitization, nasopharyngeal colonization with *Streptococcus* and early febrile lower respiratory infections – factors associated with asthma in this cohort^[110] – suggesting that an effect of vitamin D deficiency on subsequent asthma may be partly modulated by allergic sensitization, respiratory tract bacterial colonization and/or infection in infancy.^[109] This suggests that preventing vitamin D deficiency throughout childhood may be important in the prevention of these disorders.

The efficacy of vitamin D is better established for the management than for the prevention of asthma. A Cochrane review of placebo-controlled trials, including 435 children and 658 adults, concluded that vitamin D is likely to reduce the risk of severe asthma exacerbation and healthcare use because of asthma, though children and those with severe asthma were underrepresented in the included studies.^[111] These findings are in accordance with other systematic reviews.^[112,113]

As many processes affected by vitamin D begin before or shortly after birth, there has been considerable interest in a possible role of prenatal and early life vitamin D supplementation in asthma prevention.^[104] Observational studies, though heterogeneous and inconsistent, and a growing body of clinical trial data suggest a protective effect of vitamin D supplementation during pregnancy and early infancy.^[114–117] This and other prenatal interventions are reviewed in detail in this issue by Tina Hartert.

The dose of vitamin D needed for prevention remains undefined. In pregnancy, doses of 2400–4400 IU daily appear safe.^[116,117] However, a single-dose recommendation for all patients may not suffice, and future studies will need to define whether a level-based dosing regimen (i.e. to target a prespecified level) may be a better strategy. Likewise, in infancy and early childhood, the dose of vitamin D supplementation or the desired level of 25-hydroxyvitamin D to prevent asthma remains undefined. The study by Hollams *et al.*^[109] will need to be verified in other cohorts. The current recommended daily allowance for vitamin D in children is 600 IU daily.^[118] However, given the high prevalence of vitamin D deficiency in many countries, it remains to be seen whether individualized supplementation to target a specified level in children rather than prescribing a specific intake for all children will be more effective in preventing the development of asthma.

Conclusion

The determinants of the diverse trajectories of lung function and asthma morbidity that are observed throughout the lifespan remain to be fully defined. This area of study progresses in parallel with and enables the recognition of risk factors for asthma and the evaluation of interventions to reduce asthma risk. We have highlighted active areas of research, including the search for medical treatments that could be given in the preschool years to prevent persistent wheeze, the undefined role of e-cigarette use in smokers with asthma and whether microbial exposures can be manipulated to reduce asthma risk. These lines of investigation will hopefully yield additions to the armamentarium of effective strategies to modify the natural history of asthma. Evidence is accumulating that reducing air pollution and avoiding vitamin D deficiency in childhood lead to improved outcomes, and attention should be paid to these exposures.

Sidebar

Key Points

- Efforts are ongoing to describe and predict trajectories of asthma occurrence and severity over the lifespan.

- A large and growing body of evidence has linked microbial exposures and risk of allergic disease, and the use of bacterial lysates in asthma prevention is currently under study.
- Interventions to reduce air pollution are feasible, result in demonstrable improvement in lung function development and may have the greatest impact during prenatal and early life.
- The health effects of e-cigarette use in those with asthma must be clarified before a role of e-cigarette use in smokers with asthma can be defined.
- Vitamin D plays an important role in immune and pulmonary development, and vitamin D supplementation reduces asthma exacerbations in adults with mild-to-moderate asthma.

References

1. Yunginger JW1, Reed CE, O'Connell EJ, *et al*. A community-based study of the epidemiology of asthma. Incidence rates, 1964–1983. *Am Rev Respir Dis* 1992; 146:888–894.
2. Haaland G, Carlsen KC, Sandvik L, *et al*. Reduced lung function at birth and the risk of asthma at 10 years of age. *N Engl J Med* 2006; 355:1682–1689.
3. Turner SW, Palmer LJ, Rye PJ, *et al*. The relationship between infant airway function, childhood airway responsiveness, and asthma. *Am J Resp Crit Care Med* 2004; 169:921–927.
4. Bisgaard H, Jensen SM, Bønnelykke K. Interaction between asthma and lung function growth in early life. *Am J Resp Crit Care Med* 2012; 185:1183–1189.
5. Ducharme FM, Tse SM, Chauhan B. Asthma 2: diagnosis, management and prognosis of preschool wheeze. *Lancet* 2014; 383:1593–1604.
6. Bacharier LB, Guilbert TW. Diagnosis and management of early asthma in preschool-aged children. *J Allergy Clin Immunol* 2012; 130:287–296.
7. Martinez FD, Wright AL, Taussig LM, *et al*. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. *N Engl J Med* 1995; 332:133–138.
8. Castro-Rodríguez JA, Holberg CJ, Wright AL, *et al*. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Resp Crit Care Med* 2000; 162:1403–1406.
9. Luo G, Nkoy FL, Stone BL, *et al*. A systematic review of predictive models for asthma development in children. *BMC Med Inform Decis Mak* 2015; 15:99.
10. Howard R, Rattray M, Posperi M, *et al*. Distinguishing asthma phenotypes using machine learning approaches. *Curr Allergy Asthma Rep* 2015; 15:38.
11. Savenije OE, Granell R, Caudri D, *et al*. Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA. *J Allergy Clin Immunol* 2011; 127:1505–1512; e14.
12. Covar RA, Strunk R, Zeiger RS, *et al*. Predictors of remitting, periodic, and persistent childhood asthma. *J Allergy Clin Immunol* 2010; 125:359.
13. Andersson M, Hedman L, Bjerg A, *et al*. Remission and persistence of asthma followed from 7 to 19 years of age. *Pediatrics* 2013; 132:e435.
14. Martin AJ, Landau LI, Phelan PD. Lung function in young adults who had asthma in childhood. *Am Rev Respir Dis* 1980; 122:609.

15. Kelly WJ, Hudson I, Raven J, *et al.* Childhood asthma and adult lung function. *Am Rev Respir Dis* 1988; 138:26.
16. Godden DJ, Ross S, Abdalla M, *et al.* Outcome of wheeze in childhood. Symptoms and pulmonary function 25 years later. *Am J Resp Crit Care Med* 1994; 149:106.
17. McGeachie MJ, Yates KP, Zhou F, *et al.* Patterns of growth and decline in lung function in persistent childhood asthma. *N Engl J Med* 2016; 374:1842–1852.
** This longitudinal study identifies patterns of lung function growth and decline and their risk factors in children with asthma followed to early adulthood.
18. Kaiser SV, Huynh T, Bacharier LB, *et al.* Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis. *Pediatrics* 2016; 137:e20154496.
19. Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. *Pediatrics* 2009; 123:e519–e525.
20. Chong J, Haran C, Chauhan BF, Asher I. Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults. *Cochrane Database Syst Rev* 2015; 7:CD011032.
21. Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. *Cochrane Database Syst Rev* 2013; 2:CD009611.
22. Brodlie M, Gupta A, Rodriguez-Martinez CE, *et al.* Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children. *Cochrane Database Syst Rev* 2015; 10:CD008202.
23. Fitzpatrick AM, Jackson DJ, Mauger DT, *et al.* Individualized therapy for persistent asthma in young children. *J Allergy Clin Immunol* 2016; 138:1608–1618.e12.
24. Guilbert TW, Morgan WJ, Zeiger RS. Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med* 2006; 354:1985–1997.
25. Murray CS, Woodcock A, Langley SJ, *et al.* Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. *Lancet* 2006; 368:754–762.
26. Bisgaard H, Hermansen MN, Loland L, *et al.* Intermittent inhaled corticosteroids in infants with episodic wheezing. *N Engl J Med* 2006; 354:1998–2005.
27. Akinbami LJ, Kit BK, Simon AE. Impact of environmental tobacco smoke on children with asthma, United States, 2003–2010. *Acad Pediatr* 2013; 13:508.
28. Lange P, Parner J, Vestbo J, *et al.* A 15-year follow-up study of ventilator function in adults with asthma. *N Engl J Med* 1998; 339:1194.
29. Apostol GG, Jacobs DR Jr, Tsai AW, *et al.* Early life factors contribute to the decrease in lung function between age 18 and 40: the Coronary Artery Risk Development in Young Adults study. *Am J Resp Crit Care Med* 2002; 166:166.
30. Althius MD, Sexton M, Prybylski D. Cigarette smoking and asthma symptom severity among adult asthmatics. *J Asthma* 1999; 36:257.
31. Siroux V, Pin I, Oryszczyn MP, *et al.* Relationships of active smoking to asthma and asthma severity in the EGEA study. *Eur Respir J* 2000; 15:470.

32. Tonnesen P, Pisinger C, Hvidberg S, *et al*. Effects of smoking cessation and reduction in asthmatics. *Nicotine Tob Res* 2005; 7:139–148.
33. Chaudhuri R, Livingston E, McMahon AD, *et al*. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. *Am J Resp Crit Care Med* 2006; 174:127–133.
34. Polosa R, Campagna D, Sands MF. Counseling patients with asthma and allergy about electronic cigarettes: an evidence-based approach. *Ann Allergy Asthma Im* 2016; 116:106–111.
* An evidence-based review of the risks and possible benefits of e-cigarette use in patients with asthma.
35. Cooke A, Fergeson J, Bulkhi A, Casale TB. The electronic cigarette: the good, the bad, and the ugly. *J Allergy Clin Immunol Pract* 2015; 3:498–505.
36. Dinakar C, O'Connor GT. The health effects of electronic cigarettes. *N Engl J Med* 2016; 375:1372–1381.
37. Delnevo CD, Giovenco DP, Steinberg MB, *et al*. Patterns of electronic cigarette use among adults in the United States. *Nicotine Tob Res* 2016; 18:715–719.
38. Kann L, McManus T, Harris WA, *et al*. Youth risk behavior surveillance: United States, 2015. *MMWR Surveill Summ* 2016; 65:1–174.
39. Singh T, Arrazola RA, Corey CG, *et al*. Tobacco use among middle and high school students: United States, 2001–2015. *MMWR Morb Mortal Wkly Rep* 2016; 65:361–367.
40. Choi K, Bernat D. E-Cigarette use among Florida youth with and without asthma. *Am J Prev Med* 2016; 51:446–453.
41. Beard E, West R, Michie S, Brown J. Association between electronic cigarette use and changes in quit attempts, success of quit attempts, use of smoking cessation pharmacotherapy, and use of stop smoking services in England: time series analysis of population trends. *BMJ* 2016; 354:i4645.
42. Kalkhoran S, Glantz SA. E-cigarette and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. *Lancet Resp Med* 2016; 4:116–128.
43. Polosa R, Marjaria J, Caponnetto P, *et al*. Persisting long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes. *Discov Med* 2016; 21:99–108.
* This study supports a possible role of e-cigarette use in those with asthma who are current smokers of conventional cigarettes.
44. Polosa R, Morjaria J, Caponnetto P, *et al*. Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic cigarettes: evidence for harm reversal. *Int J Environ Res Public Health* 2014; 11:4965–4977.
45. Leigh NJ, Lawton RI, Hershberger PA, Goniewicz ML. Flavourings significantly affect inhalation toxicity of aerosol generated from electronic nicotine delivery systems (ENDS). *Tob Control* 2016; 25 (Suppl 2):ii81–ii87.
46. Putzhammer R, Doppler C, Jakschitz T, *et al*. Vapours of US and EU market leader electronic cigarette brands and liquids are cytotoxic for human vascular endothelial cells. *PLoS One* 2016; 11:e0157337.

47. Gauderman WJ, Avol E, Gilliland F, *et al*. The effect of air pollution on lung development from 10 to 18 years of age. *N Engl J Med* 2004; 351:1057–1067.
48. Urman R, McConnell R, Islam T, *et al*. Associations of children's lung function with ambient air pollution: joint effects of regional and near-roadway pollutants. *Thorax* 2014; 69:540–547.
49. Mölter A, Agius RM, de Vocht F, *et al*. Long-term exposure to PM10 and NO2 in association with lung volume and airway resistance in the MAAS birth cohort. *Environ Health Perspect* 2013; 131:1232–1238.
50. Gehring U, Gruzieva O, Agius RM, *et al*. Air pollution exposure and lung function in children: the ESCAPE project. *Environ Health Perspec* 2013; 121:1357–1364.
51. Morales E, Garcia-Esteban R, de la Cruz OA, *et al*. Intrauterine and early postnatal exposure to outdoor air pollution and lung function at preschool age. *Thorax* 2015; 70:64–73.
52. Islam T, Gauderman WJ, Berhane K, *et al*. Relationship between air pollution, lung function and asthma in adolescents. *Thorax* 2007; 62:957–963.
53. Jung DY, Leem JH, Kim HC, *et al*. Effect of traffic-related air pollution on allergic disease: results of the Children's Health and Environmental Research. *Allergy Asthma Immun Res* 2015; 7:359–366.
54. Atkinson RW, Anderson HR, Sunyer J, *et al*. Acute effects of particulate air pollution on respiratory admissions: results from APHEA 2 project. *Air pollution and health – a European approach. Am J Resp Crit Care Med* 2001; 164:1860–1866.
55. O'Connor GT, Neas L, Vaughn B, *et al*. Acute respiratory health effects of air pollution on children with asthma in US inner cities. *J Allergy Clin Immunol* 2008; 121:1133–1139.
56. Gent JF, Triche EW, Holford TR, *et al*. Association of low-level ozone and fine particles with respiratory symptoms in children with asthma. *JAMA* 2003; 290:1859–1867.
57. Guaderman WJ, Avol E, Lurmann F, *et al*. Childhood asthma and exposure to traffic and nitrogen dioxide. *Epidemiology* 2005; 16:737–743.
58. McConnell R, Berhane K, Gilliland F, *et al*. Asthma in exercising children exposed to ozone: a cohort study. *Lancet* 2002; 359:386–391.
59. Malig BJ, Pearson DL, Chang YB, *et al*. A time-stratified case-crossover study of ambient ozone exposure and emergency department visits for specific respiratory diagnoses in California (2005–2008). *Environ Health Perspect* 2016; 124:745–753.
60. D'Amato G, Vitale C, LanzaM, *et al*. Climate change, air pollution, and allergic respiratory diseases: an update. *Curr Opin Allergy CI* 2016; 16:434–440.
* A review of current evidence regarding the effects of air pollution and climate change on allergic respiratory disease.
61. Schultz ES, Hallberg J, Bellander T, *et al*. Early-life exposure to traffic-related air pollution and lung function in adolescence. *Am J Resp Crit Care Med* 2016; 193:171–177.
* This birth cohort study shows an impact of air pollution exposure during early life, and especially during infancy, on lung function at age 16.
62. Schultz ES, Gruzieva O, Bellander T, *et al*. Traffic-related air pollution and lung function in children at 8 years of age: a birth cohort study. *Am J Resp Crit Care Med* 2012; 186:1286–1291.

63. Sbihi H, Koehoorn M, Tamburic L, Brauer M. Asthma trajectories in a population-based birth cohort: Impacts of air pollution and greenness. *Am J Resp Crit Care Med* 2016; DOI: 10.1164/rccm.201601-202164. [Epub ahead of print]
64. Gauderman WJ, Urman R, Avol E, *et al.* Association of improved air quality with lung development in children. *N Engl J Med* 2015; 372:905–913.
** This important study shows that air pollution reduction interventions can improve air quality and have positive effects on lung function growth in children both with and without asthma.
65. Friedman MS, Powell KE, Hutwagner L, *et al.* Impact of changes in transportation and commuting behaviors during the 1996 Summer Olympic Games in Atlanta on air quality and childhood asthma. *JAMA* 2001; 285:897–905.
66. Li Y, Wang W, Wang J, *et al.* Impact of air pollution control measures and weather conditions on asthma during the 2008 Summer Olympic Games in Beijing. *Int J Biometeorol* 2011; 55:547–554.
67. Li Y, Wang W, Kan H, *et al.* Air quality and outpatient visits for asthma in adults during the 2008 Summer Olympic Games in Beijing. *Sci Total Environ* 2010; 408:1226–1227.
68. von Mutius E. The microbial environment and its influence on asthma prevention in early life. *J Allergy Clin Immunol* 2016; 137:680–689.
* A comprehensive review of determinants and interactions between environmental and human microbial communities and the influence of microbial exposures on immune maturation and risk of allergic disease.
69. Johnson CC, Ownby DR. The infant gut bacterial microbiota and risk of pediatric asthma and allergic diseases. *Transl Res* 2017; 179:60–70.
70. Strachan DP. Hay fever, hygiene, and household size. *BMJ* 1989; 299:1259–1260.
71. Wu P, Feldman AS, Rosas-Salazar C, *et al.* Relative importance and additive effects of maternal and infant risk factors on childhood asthma. *PLoS One* 2016; 11:e0151705.
* This birth cohort study investigated several exposures that may alter human microbial composition and showed that these exposures are associated with increased risk of childhood asthma.
72. Lynch SV, Boushey HA. The microbiome and development of allergic disease. *Curr Opin Allergy CI* 2016; 16:165–171.
* An update on recent evidence regarding the human gut and respiratory microbiomes and their relationships with immune development and risk of allergic disease.
73. Rosas-Salazar C, Shilts MH, Tovchigrechko A, *et al.* Nasopharyngeal microbiome in respiratory syncytial virus resembles profile associated with increased childhood asthma risk. *Am J Resp Crit Care Med* 2016; 193:1180–1183.
74. Arrieta MC, Stiemsma LT, Dimitriu PA, *et al.* Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med* 2015; 7:307ra152.
75. Hevia A, Milani C, López P, *et al.* Allergic patients with long-term asthma display low levels of *Bifidobacterium adolescentis*. *PLoS One* 2016; 11:e0147809.
76. Hua X, Goedert JJ, Pu A, *et al.* Allergy associations with the adult fecal microbiota: analysis of the American Gut Project. *EBioMedicine* 2016; 3:172–179.

77. Björkstén B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. *Clin Exp Allergy* 1999; 29:342–346.
78. Björkstén B, Sepp E, Julge K, *et al.* Allergy development and the intestinal microflora during the first year of life. *J Allergy Clin Immunol* 2001; 108:516–520.
79. Kalliomäki M, Kirjavainen P, Eerola E, *et al.* Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. *J Allergy Clin Immunol* 2001; 107:129–134.
80. Bisgaard H, Hermansen MN, Buchvald F, *et al.* Childhood asthma after bacterial colonization of the airway in neonates. *N Engl J Med* 2007; 357:1487–1495.
81. Teo SM, Mok D, Pham K, *et al.* The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* 2015; 17:704–715.
82. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell* 2014; 157:121–141.
83. Debarry J, Garn H, Hanuszkiewicz A, *et al.* *Acinetobacter lwoffii* and *Lactococcus lactis* strains isolated from farm cowsheds possess strong allergyprotective properties. *J Allergy Clin Immunol* 2007; 119:1514–1521.
84. Hagner S, Harb H, Zhao M, *et al.* Farm-derived gram-positive bacterium *Staphylococcus sciuri* w620 prevents asthma phenotype in HDM- and OVAexposed mice. *Allergy* 2013; 68:322–329.
85. Peters M, Kauth M, Scherner O, *et al.* *Arabinogalactan* isolated from cowshed dust extract protects mice from allergic airway inflammation and sensitization. *J Allergy Clin Immunol* 2010; 126:648–656; e1–e4.
86. Stein MM, Hrusch CL, Gozdz J, *et al.* Innate immunity and asthma risk in Amish and Hutterite farm children. *N Engl J Med* 2016; 375:411–421.
* This study shows that industrial farming practices are associated with increased risk of allergic disease compared with traditional farming practices, and provides evidence that this may be accounted for by differences in microbial exposures.
87. Fujimura KE, Sitarik AR, Havstad S, *et al.* Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. *NatMed* 2016; 10:1187–1191.
88. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergy. *Cochrane Database Syst Rev* 2007; 3:CD006475.
89. Azad MB, Coneys JG, Kozyrskyj AL, *et al.* Probiotic supplementation during pregnancy or infancy for the prevention of asthma and wheeze: systematic review and meta-analysis. *BMJ* 2013; 347:f6471.
90. Zuccotti G, Meneghin F, Aceti A, *et al.* Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. *Allergy* 2015; 70:1356–1371.
91. Simpson MR, Dotterud CK, Storrø O, *et al.* Perinatal probiotic supplementation in the prevention of allergy related disease: 6 year follow up of a randomised controlled trial. *BMC Dermatol* 2015; 15:13.
92. Jensen MP, Meldrum S, Taylor AL, *et al.* Early probiotic supplementation for allergy prevention: long-term outcomes. *J Allergy Clin Immunol* 2012; 130:1209–1211; e5.
93. West CE, Hammarström ML, Hernell O. Probiotics in primary prevention of allergic disease: follow-up at 8–9 years of age. *Allergy* 2013; 68:1015–1020.

94. Abrahamsson TR, Jakobsson T, Björkstén B, *et al.* No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy. *Pediatr Allergy Immunol* 2013; 24:556–561.
95. Kearney SC, Dziekiewicz M, Feleszko W. Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. *Ann Allergy Asthma Immun* 2015; 114:364–369.
96. Navarro S, Cossalter G, Chiavaroli C, *et al.* The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. *Mucosal Immunol* 2011; 4:53–65.
97. Fu R, Li J, Zhong H, *et al.* Broncho-Vaxom attenuates allergic airway inflammation by restoring GSK3b-related T regulatory cell insufficiency. *PLoS One* 2014; 9:e92912.
98. Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-analysis. *Pulm Pharmacol & Ther* 2012; 25:62–68.
99. Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJ. Immunostimulants for preventing respiratory tract infection in children. *Cochrane Database Syst Rev* 2006; 4:CD004974.
100. Schaad UB, OM-85 BV. An immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. *World J Pediatr* 2010; 6:5–12.
101. Steurer-Stey C, Lagler L, Straub DA, *et al.* Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. *Eur J Pediatr* 2007; 166:365–376.
102. Razi CH, Harmanci K, Abaci A, *et al.* The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. *J Allergy Clin Immunol* 2010; 126:763–769.
103. Koatz AM, Coe NA, Ciceran A, Alter AJ. Clinical and immunologic benefits of OM-85 bacterial lysate in patients with allergic rhinitis, asthma, COPD and recurrent respiratory infections. *Lung* 2016; 194:687–697.
104. Mirzakhani H, Al-Garawi A, Weiss ST, Litonjua AA. Vitamin D and the development of allergic disease: how important is it? *Clin Exp Allergy* 2015; 45:114–125.
105. Mann EH, Chambers ES, Pfeffer PE, Hawrylowicz CM. Immunoregulatory mechanisms of vitamin D relevant to respiratory health and asthma. *Ann N Y Acad Sci* May 2014; 1317:57–69.
106. Zosky GR, Berry LJ, Elliot JG, *et al.* Vitamin D deficiency causes deficits in lung function and alters lung structure. *Am J Resp Crit Care Med* 2011; 183:1336–1343.
107. Kho AT, Sharma S, Qiu W, *et al.* Vitamin D related genes in lung development and asthma pathogenesis. *BMC Med Genomics* 2013; 6:47.
108. Hart PH, Lucas RM, Walsh JP, *et al.* Vitamin D in fetal development: findings from a birth cohort study. *Pediatrics* 2015; 135:e167–e173.
109. Hollams EM, Teo SM, Kusel M, *et al.* Vitamin D over the first decade and susceptibility to childhood allergy and asthma. *J Allergy Clin Immunol* 2016; DOI: 10.1016/j.jaci.2016.07.032. [Epub ahead of print]
* This study shows that longitudinal vitamin D insufficiency over infancy and childhood is associated with increased risk of asthma and wheeze at age 10.

110. Kusel M, Keadze T, Johnston S, *et al*. Febrile respiratory illnesses in infancy and atopy are risk factors for persistent asthma and wheeze. *Eur Resp J* 2012; 39:876–882.
111. Martineau AR, Cates CJ, Urashima M, *et al*. Vitamin D for the management of asthma. *Cochrane Database Syst Rev* 2016; 9:CD011511.
** This systematic review concludes that vitamin D supplementation reduces the risk of severe asthma exacerbation and healthcare use due to asthma, with the strongest evidence available in adults and those with mild asthma.
112. Xiao L, Xing C, Yang Z, *et al*. Vitamin D supplementation for the prevention of childhood acute respiratory infections: a systematic review of randomized controlled trials. *Br J of Nutrition* 2015; 114:1026–1034.
113. Riverin BD, Maguire JL, Li P. Vitamin D supplementation for childhood asthma: a systematic review and meta-analysis. *PLoS One* 2015; 10:e0136841.
114. Feng H, Xun P, Pike K, *et al*. In utero exposure to 25(OH) D and risk of childhood asthma, wheeze and respiratory tract infections: a meta-analysis of birth cohort studies. *J Allergy Clin Immunol* 2016; DOI: 10.1016/j.jaci.2016.06.065. Published online 14 September 2016.
115. Grant CC, Crane J, Mitchell EA, *et al*. Vitamin D supplementation during pregnancy and infancy reduces aeroallergen sensitization: a randomized controlled trial. *Allergy* 2016; 71:1325–1334.
116. Chawes BL, Bønnelykke K, Stokholm J, *et al*. Effect of vitamin D3 supplementation during pregnancy on risk of persistent wheeze in the offspring: a randomized clinical trial. *JAMA* 2016; 315:353–361.
117. Litonjua AA, Carey VJ, Laranjo N, *et al*. Effect of prenatal supplementation with vitamin D on asthma or recurrent wheezing in offspring by age 3 years: the VDAART randomized clinical trial. *JAMA* 2016; 315:362–370.
118. Ross AC, Taylor CL, Yaktine AL, *et al.*, editors. Dietary reference intakes for calcium and vitamin D. Washington, D.C: National Academies Press; 2010.

Acknowledgements

None.

Financial support and sponsorship

This work was supported by NIH grant 5T32AI007306-30.

Curr Opin Allergy Clin Immunol. 2017;17(2):139-145. © 2017 Lippincott Williams & Wilkins

This website uses cookies to deliver its services as described in our [Cookie Policy](#). By using this website, you agree to the use of cookies.

[close](#)